KR20240021910A - 치환된 피롤로[2,3-d]피리미딘, 이의 제조 및 이의 치료적 용도 - Google Patents

치환된 피롤로[2,3-d]피리미딘, 이의 제조 및 이의 치료적 용도 Download PDF

Info

Publication number
KR20240021910A
KR20240021910A KR1020247001337A KR20247001337A KR20240021910A KR 20240021910 A KR20240021910 A KR 20240021910A KR 1020247001337 A KR1020247001337 A KR 1020247001337A KR 20247001337 A KR20247001337 A KR 20247001337A KR 20240021910 A KR20240021910 A KR 20240021910A
Authority
KR
South Korea
Prior art keywords
group
groups
methyl
substituted
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001337A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 베르나르델리
스테파니 드프레
로랑 뒤부아
존 마코
프레데릭 쁘띠
코린 테리에
마크 비앙쇼토
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by 사노피 filed Critical 사노피
Publication of KR20240021910A publication Critical patent/KR20240021910A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
KR1020247001337A 2021-06-15 2022-06-14 치환된 피롤로[2,3-d]피리미딘, 이의 제조 및 이의 치료적 용도 Pending KR20240021910A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21315095.6 2021-06-15
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
EP22315117.6 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (1)

Publication Number Publication Date
KR20240021910A true KR20240021910A (ko) 2024-02-19

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001337A Pending KR20240021910A (ko) 2021-06-15 2022-06-14 치환된 피롤로[2,3-d]피리미딘, 이의 제조 및 이의 치료적 용도

Country Status (11)

Country Link
US (1) US20240383901A1 (https=)
EP (1) EP4355748A1 (https=)
JP (1) JP2024525150A (https=)
KR (1) KR20240021910A (https=)
AU (1) AU2022294022A1 (https=)
BR (1) BR112023025042A2 (https=)
CA (1) CA3223786A1 (https=)
CO (1) CO2024000083A2 (https=)
IL (1) IL309195A (https=)
MX (1) MX2023015016A (https=)
WO (1) WO2022263472A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025141029A1 (en) * 2023-12-27 2025-07-03 Sanofi Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
CN106146515B (zh) * 2015-04-17 2020-09-04 常州隆赛医药科技有限公司 新型激酶抑制剂的制备及应用
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Also Published As

Publication number Publication date
IL309195A (en) 2024-02-01
BR112023025042A2 (pt) 2024-02-27
MX2023015016A (es) 2024-05-31
AU2022294022A1 (en) 2024-02-01
CA3223786A1 (en) 2022-12-22
CO2024000083A2 (es) 2024-04-08
EP4355748A1 (en) 2024-04-24
JP2024525150A (ja) 2024-07-10
WO2022263472A1 (en) 2022-12-22
US20240383901A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
US12077536B2 (en) BCL-2 inhibitors
KR102283091B1 (ko) Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
CN116888108B (zh) 新型egfr降解剂
EP2569314B1 (en) Fused bicyclic kinase inhibitors
JP2024519496A (ja) ブルトンのチロシンキナーゼの分解を標的化するための化合物
JP7839790B2 (ja) Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体
JP2023523863A (ja) 新規大環状ｌｒｒｋ２キナーゼインヒビター
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN115209952B (zh) 经取代的吡唑并嘧啶及其用途
CN119403806A (zh) Trem2调节剂
KR20240021910A (ko) 치환된 피롤로[2,3-d]피리미딘, 이의 제조 및 이의 치료적 용도
TW202317106A (zh) 作為egfr抑制劑之取代胺基吡啶化合物
US20250313575A1 (en) Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US12570640B2 (en) 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
CN116322692A (zh) 自分泌运动因子抑制剂化合物
EP4219500A1 (en) Condensed heterocyclic compound
EP4105218A1 (en) Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
CN117881681A (zh) 经取代的吡咯并[2,3-d]嘧啶、其制备及其治疗应用
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
WO2024061118A1 (zh) 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
HK40117006A (zh) 新颖杂环化合物
EA048670B1 (ru) Макроциклические ингибиторы lrrk2 киназы
MD4313293T2 (ro) Derivati de tetrahidrotienopiridine ca inhibitori DDR

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250529

Comment text: Request for Examination of Application